Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Financing Activities: 2011-2025

Historic Cash from Financing Activities for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $15.4 million.

  • Aytu Biopharma's Cash from Financing Activities rose 152.03% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 606.17%. This contributed to the annual value of $15.4 million for FY2025, which is 1323.69% up from last year.
  • Latest data reveals that Aytu Biopharma reported Cash from Financing Activities of $15.4 million as of FY2025, which was up 1,323.69% from -$1.3 million recorded in FY2024.
  • Over the past 5 years, Aytu Biopharma's Cash from Financing Activities peaked at $30.3 million during FY2021, and registered a low of -$1.3 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is $7.7 million, with a median of $8.9 million in 2023.
  • As far as peak fluctuations go, Aytu Biopharma's Cash from Financing Activities crashed by 114.23% in 2024, and later spiked by 1,323.69% in 2025.
  • Aytu Biopharma's Cash from Financing Activities (Yearly) stood at $30.3 million in 2021, then slumped by 94.95% to $1.5 million in 2022, then surged by 479.80% to $8.9 million in 2023, then crashed by 114.23% to -$1.3 million in 2024, then spiked by 1,323.69% to $15.4 million in 2025.